Pharma News

Menarini Asia-Pacific partner of Moberg Pharma AB, a Swedish pharmaceutical company, has initiated the launch of Kerasal Nail, a topical treatment used to treat nail disease, in China.  Moberg Pharma’s distribution agreement with the Menarini Group – a top 40 global pharmaceutical company - includes Italy, China and eight countries in Southeast Asia. Launch activities have previously been initiated in Malaysia, Singapore and Hong Kong.

Daiichi Sankyo Company, Limited has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) for its influenza HA vaccine “Kaketsuken.” As per  Agreement, sales activities of Kaketsuken will begin by Daiichi Sankyo from next season (2015-2016).

[adsense:336x280:8701650588]

Philips has launched the ClearVue Elite range of affordable ultrasound solutions. The product is designed with a high level of performance at an affordable price. This new generation power system has faster processing, superior performance and better output, including faster 4D volume rates that aids in capturing fetal movements. It features Philips proprietary Active Array technology that reduces bulky circuitry and integrates key broadband beam forming capabilities into the transducer, resulting in excellent image quality.

Actavis plc has introduced Namzaric, a once-daily, fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist), and donepezil hydrochloride (an acetylcholinesterase inhibitor) across the United States. Namzaric was approved by the US Food and Drug Administration (FDA) in December for the treatment of moderate to severe Alzheimer's disease in patients stabilized on memantine hydrochloride and donepezil hydrochloride.

An autonomous body under the AYUSH department of Union Health Ministry is planning to tieup with top homeopathy research organisations with an aim of boosting the healthcare industry. The Central Council for Research in Homeopathy (CCRH), the autonomous body under AYUSH, has called for further research to promote this system of medicine, said Dr R K Manchanda, Director General of CCRH.

India and Canada will partner in health innovations in India focussing on maternal, newborn and child health and Visceral Leishmaniasis elimination and will make an invest of US dollar 2.5 million. The Department of Biotechnology (DBT) and Grand Challenges Canada (GCC), funded by the Government of Canada, will work to eliminate Visceral Leishmaniasis (VL, Kala Azar) in Bihar.

Eli Lilly and Sanford-Burnham, a non-profit medical research institute, will develop potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren's Syndrome, inflammatory bowel disease and other autoimmune disorders. This high degree of interaction will allow the organizations to flexibly and efficiently advance projects to clinical investigation. The research collaboration will be co-chaired by Thomas F.

AstraZeneca, innovation-driven biopharmaceutical business,  to invest approximately $285 million in a new facility for manufacturing of biological medicines in Södertälje, Sweden. Södertälje is currently main Place to AstraZeneca’s largest global tablets and capsules manufacturing facility. Company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden operations unit.
The new plant will be focused on filling and packaging of protein therapeutics.

Strides Arcolab Limited has got approval from the United States Food & Drug Administration (FDA) for lamivudine and zidovudine tablets USP, 150 mg/300 mg for HIV therapy.